ERT has launched its refreshed eCOA technology environment, with enhanced features on the back-end to make eCOA easier for patients to use, and more cost effective and faster for sponsors to implement.
ERT has launched its refreshed eCOA technology environment, with enhanced features on the back-end to make eCOA easier for patients to use, and more cost effective and faster for sponsors to implement. The goal is to address potential misconceptions that eCOA is cumbersome, which will lead to broader eCOA adoption within the industry.
Read the full release here
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.